Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

… Sean Wharton reports receiving honoraria and travel expenses and has participated in
academic advisory boards for Novo Nordisk, Bausch Health, Eli Lilly and Janssen. Sean Wharton …

Background Obesity is a major public health issue, and new pharmaceuticals for weight
management are needed. Therefore, we evaluated the efficacy and safety of the glucagon-like …

Background Obesity is a chronic disease that results in substantial global morbidity and
mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic …

Objective Real‐world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and
exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent …

Aim We evaluated gastrointestinal (GI) adverse events (AEs) with once‐weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL). …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide
2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults …

Background Obesity is a major risk factor for many leading causes of illness and death
worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like …

Aim To explore changes in body weight and cardiometabolic risk factors after treatment
withdrawal in the STEP 1 trial extension. Materials and Methods STEP 1 (NCT03548935) …

Obesity, one of the most prevalent health problems in the Western world, is a chronic and
progressive condition. Therefore, as with other chronic diseases, patients with obesity require …